SSRI (Selective Serotonin Reuptake Inhibitor)
Pregnancy: Use only if benefit outweighs risk. Neonatal adaptation syndrome if used near term. Persistent pulmonary hypertension of newborn (very rare).
Sertraline
Brand names: Lustral, Zoloft
Adult dose
Dose: 50 mg once daily; increase to 100–200 mg if needed
Route: Oral
Frequency: Once daily (morning or evening)
Max: 200 mg/day
Depression/PTSD: start 50 mg OD, increase by 50 mg every 4–7 days to target (100–200 mg). OCD: start 50 mg, titrate up to 200 mg/day. Panic disorder: start 25 mg for 1 week then 50 mg. PMDD: 50 mg daily or during luteal phase only. Allow 4–6 weeks for full antidepressant effect.
Paediatric dose
Route: Oral
Frequency: Once daily
Max: 200 mg/day
OCD (6–17 years): 25 mg once daily (6–12 years); 50 mg once daily (13–17 years). Increase after 1 week to 50 mg/day (6–12) or 100 mg/day (13–17), max 200 mg/day. Not licensed for depression in under 18s in UK.
Dose adjustments
Renal
No dose adjustment required.
Hepatic
Reduce dose in hepatic impairment; use with caution.
Clinical pearls
- First-line SSRI for most conditions — best evidence for PTSD and OCD
- Sexual side effects may persist — address proactively (dose reduction, drug holiday strategy, switching)
- Monitor for suicidal ideation in adolescents/young adults in first 1–4 weeks
- SIADH more common in elderly — check serum sodium
- Discontinuation syndrome (headache, dizziness, 'brain zaps') — taper before stopping
Contraindications
- MAO inhibitors (within 14 days — risk of serotonin syndrome)
- Pimozide (QT prolongation)
- Hypersensitivity to sertraline
Side effects
- Nausea and GI upset (most common, usually transient)
- Insomnia or somnolence
- Sexual dysfunction (reduced libido, delayed ejaculation, anorgasmia)
- Headache
- Increased anxiety or agitation (initial — start low)
- Suicidal ideation in young people (monitor closely)
- Hyponatraemia (SIADH — especially elderly)
- QT prolongation (rare)
Interactions
- MAOIs — serotonin syndrome (fatal — 14-day washout required)
- Triptans — serotonin syndrome risk
- Tramadol — serotonin syndrome risk
- Anticoagulants (warfarin) — increased bleeding risk
- NSAIDs — increased GI bleeding risk
- Pimozide — contraindicated (QT prolongation)
Monitoring
- Mood and suicidality (especially early)
- Serum sodium (elderly)
- Body weight
- Sexual function
Reference: BNFc; BNF; NICE CG90 Depression; NICE NG116 PTSD; BNFc. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Drugs
Pathways
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF
- Alcohol Withdrawal Management · NICE CG115 2010 / BNF
- Eating Disorder Assessment · NICE CG9 2017 / MARSIPAN
- Serotonin syndrome · Hunter criteria (Dunkley 2003); TOXBASE/NPIS; BNF